Roche Kadcyla OK, drugs cleared as safe after EU probe PharmaTimes The therapies covered by the probe included many of its big-earning cancer drugs such as MabThera/Rituxan (rituximab), Herceptin (trastuzumab), Avastin (bevacizumab) and Tarceva (erlotinib), as well as RoActemra/Actemra (tocilizumab) for rheumatoid ... |
